{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T07:38:13Z","timestamp":1769067493560,"version":"3.49.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","cysticfibrosisjournal.com","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.jcf.2024.03.004","type":"journal-article","created":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T22:27:38Z","timestamp":1710282458000},"page":"1159-1162","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Creation of a CF-specific antibiotic spectrum index (ASI) as an antimicrobial stewardship initiative"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0382-6858","authenticated-orcid":false,"given":"Jonathan D.","family":"Cogen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonya L.","family":"Heltshe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5973-4965","authenticated-orcid":false,"given":"Adam W.","family":"Brothers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5727-8164","authenticated-orcid":false,"given":"Donald R.","family":"VanDevanter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey S.","family":"Gerber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1856-6841","authenticated-orcid":false,"given":"Matthew P.","family":"Kronman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ranjani","family":"Somayaji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.jcf.2024.03.004_bib0001","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1002\/ppul.22652","article-title":"Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis","volume":"48","author":"Wagener","year":"2013","journal-title":"Pediatr Pulmonol"},{"issue":"2","key":"10.1016\/j.jcf.2024.03.004_bib0002","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2016-2642","article-title":"Characterization of inpatient cystic fibrosis pulmonary exacerbations","volume":"139","author":"Cogen","year":"2017","journal-title":"Pediatrics"},{"key":"10.1016\/j.jcf.2024.03.004_bib0003","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1378\/chest.123.1.20","article-title":"Factors influencing outcomes in cystic fibrosis: a center-based analysis","volume":"123","author":"Johnson","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.jcf.2024.03.004_bib0004","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/ppul.23147","article-title":"Antibiotic treatment of signs and symptoms of pulmonary exacerbations: a comparison by care site","volume":"50","author":"Schechter","year":"2015","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2024.03.004_bib0005","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1136\/thx.2009.131532","article-title":"Side effects of aminoglycosides on the kidney, ear and balance in cystic fibrosis","volume":"65","author":"Prayle","year":"2010","journal-title":"Thorax"},{"key":"10.1016\/j.jcf.2024.03.004_bib0006","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jcf.2017.01.006","article-title":"The cumulative effects of intravenous antibiotic treatments on hearing in patients with cystic fibrosis","volume":"16","author":"Garinis","year":"2017","journal-title":"J Cystic Fibrosis"},{"key":"10.1016\/j.jcf.2024.03.004_bib0007","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1136\/thx.2007.088757","article-title":"Case-control study of acute renal failure in patients with cystic fibrosis in the UK","volume":"63","author":"Smyth","year":"2008","journal-title":"Thorax"},{"key":"10.1016\/j.jcf.2024.03.004_bib0008","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jcf.2020.02.012","article-title":"Finding the relevance of antimicrobial stewardship for cystic fibrosis","volume":"19","author":"Cogen","year":"2020","journal-title":"J. Cystic Fibrosis"},{"key":"10.1016\/j.jcf.2024.03.004_bib0009","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s40506-018-0157-9","article-title":"Antimicrobial stewardship in the treatment of infections among patients with cystic fibrosis","volume":"10","author":"Bhowmick","year":"2018","journal-title":"Curr Treat Options Infect Dis"},{"issue":"7","key":"10.1016\/j.jcf.2024.03.004_bib0010","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1513\/AnnalsATS.201401-034OI","article-title":"Is there a role for antimicrobial stewardship in cystic fibrosis?","volume":"11","author":"Waters","year":"2014","journal-title":"Ann Am Thorac Soc"},{"issue":"S2","key":"10.1016\/j.jcf.2024.03.004_bib0011","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1093\/jpids\/piac071","article-title":"Antimicrobial stewardship in cystic fibrosis","volume":"11","author":"Lloyd","year":"2022","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"8","key":"10.1016\/j.jcf.2024.03.004_bib0012","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1017\/ice.2017.94","article-title":"Development and application of an antibiotic spectrum index for benchmarking antibiotic selection patterns across hospitals","volume":"38","author":"Gerber","year":"2017","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.jcf.2024.03.004_bib0013","unstructured":"Drug Approvals and Databases. U.S. Food & Drug Administration. https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/drug-approvals-and-databasesAccessed September 6th, 2023."},{"key":"10.1016\/j.jcf.2024.03.004_bib0014","unstructured":"Lexicomp: Evidence-Based Drug Referential Content. https:\/\/www.wolterskluwer.com\/en\/solutions\/lexicomp. Accessed September 6th, 2023."},{"key":"10.1016\/j.jcf.2024.03.004_bib0015","unstructured":"Sanford Guide. https:\/\/www.sanfordguide.com\/Accessed September 6th, 2023."},{"key":"10.1016\/j.jcf.2024.03.004_bib0016","series-title":"Antibacterial agents in clinical development: an analysis of the antibacterial clinical development pipeline, including tuberculosis","year":"2017"},{"key":"10.1016\/j.jcf.2024.03.004_bib0017","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1055\/s-0034-1396929","article-title":"Stenotrophomonas,Achromobacter, and Nonmelioid Burkholderia species. Antimicrobial resistance and therapeutic strategies","volume":"36","author":"Abbott","year":"2015","journal-title":"Semin Respir Crit Care Med"},{"issue":"9","key":"10.1016\/j.jcf.2024.03.004_bib0018","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1093\/cid\/ciab525","article-title":"Association between number of intravenous antipseudomonal antibiotics and clinical outcomes of pediatric cystic fibrosis pulmonary exacerbations","volume":"73","author":"Cogen","year":"2021","journal-title":"Clin. Infect. Dis."},{"issue":"11","key":"10.1016\/j.jcf.2024.03.004_bib0019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ofid\/ofab508","article-title":"Assessment of antibiotic de-escalation by spectrum score in patients Withi nosocomial Pneumonia: a single-center, retrospective cohort study","volume":"8","author":"Ilges","year":"2021","journal-title":"Open Forum Infect. Dis."},{"issue":"5","key":"10.1016\/j.jcf.2024.03.004_bib0020","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1093\/jac\/dkad082","article-title":"Trends in antibiotic selection pressure generated in primary care and their association with sentinenl antimicrobial resistance patterns in Europe","volume":"78","author":"Sijborm","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jcf.2024.03.004_bib0021","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1086\/677633","article-title":"Development of an antibiotic spectrum score based on veterans affairs culture and susceptibility data for the purpose of measuring antibiotic de-escalation: a modified Delphi approach","volume":"9","author":"Madaras-Kelly","year":"2014","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"2","key":"10.1016\/j.jcf.2024.03.004_bib0022","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jcf.2019.01.008","article-title":"Antimicrobial susceptibility testing (AST) and associated clinical outcomes in individuals with cystic fibrosis: a systematic review","volume":"18","author":"Somayaji","year":"2019","journal-title":"J Cyst Fibros"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324000328?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324000328?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T19:26:22Z","timestamp":1733253982000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199324000328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S1569199324000328"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2024.03.004","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Creation of a CF-specific antibiotic spectrum index (ASI) as an antimicrobial stewardship initiative","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2024.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}